Panel, Conference Presentation
Smart on Science: How Today's Patients Are Driving Cures
Milken InstituteKim McCleary, Bray Patrick Lake, Joe Selby, Mace Rothenberg, Lou DiGennaro, Tony Coles, Dr. Francis Collins
- Patient advocacy is projected to fundamentally reshape drug development by influencing trial design earlier, defining meaningful outcomes beyond traditional metrics, and securing a number-one priority status through legislative efforts like the 21st Century Cures Act and upcoming user fee cycles.
- The Precision Medicine Initiative plans to enroll a cohort of 1 million people across the United States to leverage electronic health records for big data analysis, aiming to link patient genomes with disease states and generate insights on neurodegenerative conditions 10 to 15 years into the future.
- Clinical trial methodologies are expected to shift toward enrollment based on specific driver mutations rather than tissue of origin, with full approval potentially granted via single-arm trials for certain conditions while subsequent studies confirm results.
- Technological convergence is anticipated to deliver real-time data from wearables and tech-based devices, while electronic health records will facilitate an open science mindset where data is shared among providers, researchers, and patients rather than remaining siloed.
- New collaborative coalitions involving pharmaceutical companies, academic centers, patient advocacy organizations, and government entities are predicted to emerge, with patient groups pooling resources and industry sponsors sharing data with both peers and the public.
- Future frameworks and patient preference data will focus on previously under-studied outcomes such as pain, immobility, cognitive issues, fatigue, and depression, with expectations that increased patient involvement in defining benefits and risks will improve adherence and adoption.
- A significant trend toward cultural change is expected within five years, moving the healthcare system from an adversarial stance to one of trust and cooperation, though the successful enrollment of a million individuals relies on the creation of a user-centric platform currently missing from the sector.
- Aggregate data from patient cohorts is forecast to reveal patterns significantly enhancing the understanding of patient information by 2020, while new drug development approaches aim to utilize prospective data to capture signals previously unconsidered.
- Industry participants will increasingly rely on patient contributions of ideas, suggestions, and investment rather than solely on biological samples or financial support, supported by new frameworks on patient preference scheduled for release in May.
- While the 21st Century Cures Act aims to accelerate drug development and reduce costs, success depends on the healthcare system's ability to create platforms that encourage user participation and foster an environment where stakeholders do not revert to previous practices once patient-centered approaches are adopted.